Med BioGene Reports No Revenues, $164K Loss for Q1

During the past few months, the genomic test development firm has signed a deal to develop and commercialize its NSCLC test and completed a private placement.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories